Abstract Number: 1881 • 2018 ACR/ARHP Annual Meeting
Discovery and Validation of Novel Disease Subsets in 806 Patients with Takayasu’s Arteritis across Four International Cohorts
Background/Purpose: Takayasu’s arteritis (TAK) is characterized by variable patterns of damage throughout the large arteries. This study aimed to develop and validate a novel disease…Abstract Number: 2814 • 2018 ACR/ARHP Annual Meeting
Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs
Background/Purpose: Methotrexate (MTX) has been associated with reduced risk for cardiovascular disease (CVD) in several studies conducted among rheumatoid arthritis (RA) patients never exposed to…Abstract Number: 505 • 2018 ACR/ARHP Annual Meeting
Impact of Biological Treatment on Left Ventricular Regional Dysfunction in Rheumatoid Arthritis Patients Determined with Global Circumferential and Longitudinal Strain Values Using Cardiac Magnetic Resonance Imaging
Background/Purpose: Congestive heart failure (CHF) is a major contributor to morbidity and mortality in patients with rheumatoid arthritis (RA). Myocardial disease is typically clinically silent,…Abstract Number: 805 • 2018 ACR/ARHP Annual Meeting
Diastolic Dysfunction in Scleroderma: An Investigation into Associated Risk Factors and Impact on Survival
Background/Purpose: Scleroderma heart disease often goes unrecognized until severe clinical manifestations are present. Diastolic dysfunction (DD) may identify patients at risk for cardiac complications by…Abstract Number: 1565 • 2018 ACR/ARHP Annual Meeting
Comorbidity Burden in Primary Sjögren’s Syndrome: A Long-Term Observation in Clinical Practice
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a complex disorder that may affect any organ and system. In this new era of personalized medicine, a growing…Abstract Number: 1913 • 2018 ACR/ARHP Annual Meeting
Management of Ventricular Tachycardia and Cardiomyopathy in the Rheumatologist World: A Retrospective Review of Diagnostic Tools and Treatment Decisions for Cardiac Sarcoidosis
Background/Purpose: Cardiac sarcoidosis has been noted in 2-7% of patients with sarcoidosis. However, the incidence is >20% based on necropsy data. Given the poor yield…Abstract Number: 2817 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Disease Risk with Biologics and Tofacitinib Compared to Conventional Synthetic Dmards in Patients with Rheumatoid Arthritis
Background/Purpose: Cardiovascular disease (CVD) represents the leading cause of death in RA, accounting for ~50% of excess mortality. Disease activity, strongly linked to CVD, has…Abstract Number: 507 • 2018 ACR/ARHP Annual Meeting
Echocardiographic Markers of Right Ventricle Dysfunction in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study
Background/Purpose: Screening for cardiovascular (CV) disease in patients with rheumatoid arthritis (RA) remains controversial, however, there is agreement in considering echocardiography as the most immediate…Abstract Number: 812 • 2018 ACR/ARHP Annual Meeting
Inflammatory Stays Inflammatory: A Subgroup of Systemic Sclerosis Characterized By High Morbidity and Inflammatory Resistance to Cyclophosphamide
Background/Purpose: Elevated levels of C-reactive protein (CRP) in systemic sclerosis (SSc) have been linked to early inflammatory stages of the disease. This study has been…Abstract Number: 1589 • 2018 ACR/ARHP Annual Meeting
Cardiac Biomarkers and Carotid Atherosclerosis and Its Progression in Psoriatic Disease
Background/Purpose: Laboratory biomarkers indicative of cardiac ischemia or dysfunction improve cardiovascular (CV) risk stratification in the general population. Their utility in patients with psoriatic disease…Abstract Number: 2030 • 2018 ACR/ARHP Annual Meeting
Patients with Childhood-Onset SLE (cSLE) and Hypertension Have Consistently Higher Serum Concentrations of C3 and C4 Than Those without Hypertension
Background/Purpose: Chronic systemic inflammation, mediated in part by complement, and inadequate vascular repair mechanisms affect patients with cSLE from a young age and are associated…Abstract Number: 2818 • 2018 ACR/ARHP Annual Meeting
Galectin-3 As a Marker of Subclinical Atherosclerosis, Arterial Stiffness and Myocardial Performance in Patients with Rheumatoid Arthritis
Background/Purpose: Galectin-3 has emerged as a promising novel biomarker of cardiovascular fibrosis, that can improve cardiovascular risk stratification in high-risk populations. Rheumatoid arthritis (RA) is…Abstract Number: 508 • 2018 ACR/ARHP Annual Meeting
Non-Invasive Evaluation of Left Atrial Pressure in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study
Background/Purpose: In the last several years a higher prevalence of heart failure has been described in Rheumatoid arthritis (RA) patients, particularly heart failure with preserved…Abstract Number: 856 • 2018 ACR/ARHP Annual Meeting
Integrated mRNA and microRNA Transcriptomes of Monocytes from Antiphospholipid Syndrome Patients Identifies Molecular Networks Related to Their Atherothrombotic Status. Modulatory Effects of In Vivo Ubiquinol Supplementation
Background/Purpose: 1. To characterize the mRNAs and microRNAs transcriptomes of monocytes, key immune cells in the atherothrombotic pathology of Antiphospholipid Syndrome patients (APS). 2. To…Abstract Number: 1590 • 2018 ACR/ARHP Annual Meeting
Metabolomics Profile Predicts Carotid Atherosclerosis Progression in Psoriatic Disease
Background/Purpose: Metabolomic profiling of patients with psoriatic disease (PsD) offers unparalleled opportunity to unravel the molecular and clinical interactions linking PsD with cardiovascular (CV) risk.…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 38
- Next Page »
